Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

AFC Café: Nick geukens

  • Login to see the comments

  • Be the first to like this

AFC Café: Nick geukens

  1. 1. Complementary technologybridging as driver for translation of academic research in innovation and invention Nick Geukens
  2. 2. Setting the scene
  3. 3. Biomedical research “Long term” R&D programs  Drug development: 8-10 years “discovery to market”  Immunossay development: 2-4 years “discovery to market” Dominated by big Pharma  Growth resistors: patent cliff, global economic downturn, reduced healtcare budgets, reimbursement cuts Strategy to drive profitability = innovation (High unmet need, Improved offerings, Biologics & Emerging technologies)
  4. 4. Drug Discovery and Development: Today’s realityMaximal achievable clinical benefit with a given target Generics Best in class Follow on drug First in class 3-5 Y 5-10 Y 10-15 Y
  5. 5. The innovation challenge for a new drugMaximal achievable clinical benefit with old target Best in class Success Follow on drug Me-Too Fail First in class
  6. 6. The innovation challenge = value creation
  7. 7. Academic translational research challenge Basic research Scientific excellence New targets New Drugs New Biomarkers New Assays New Products New Services Customized Funding Key enabling technologies
  8. 8. Industrial Research Fund•Fund Flemish Government since 2004•Investment in strategic basic and applied research•Fortification of interaction between universities andindustry• “In 2012: budget ~ 19 M€ for Flemish Universities & Association with ~8 M€ for KU Leuven Association•Valorisation output:o Patentso industrial contractso EU projectso spin-offs
  9. 9. Industrial Research Fund• Activity-based funding (projects): o Leverage projects (79) o Knowledge platforms (31)• Person-based funding: o L(euvense) Da Vinci prize (3) o Industrial Research Fellows (24) http://www.kuleuven.be/industrieelonderzoeksfonds/
  10. 10. Time to value:Enabling technologiesmatching science withmedical need
  11. 11. Complementary technology bridgingScientific excellence Technology activity Enabling Technology Centers Translation of research into innovation, Center for Drug Design Innovation into inventions & and Discovery (CD3) Inventions into valorisation PharmAbs, the KU Leuven Antibody Center Portfolio of IPRs … Product pipelines
  12. 12. Bridging research and valorisation with antibodies Antibody- In vivo Spin-off Antibody Antibody based In vitro proof oftherapeutic generation & evaluation therapeutic clinical optimisation candidate Licensing concept concepttarget Spin-off Antibody- Confirmation Antibody and based reagent Assay design Assay of the clinical Licensing diagnostic & development validation development utility concept Service facility
  13. 13. Example : Towards an optimised treatment of Crohn’s patientsSTART • Assay to determine• 40% loss of response of serum level of Remicade Crohn’s disease patients in patients to Remicade® therapy • Assay to determine anti-• High number of severe drug antibody (ADA) infusion reactions formationCLINICAL OUTCOME RESEARCH OUTCOME• 2-5% loss of response of • Biochemical loss of Crohn’s disease patients response (low serum to Remicade® therapy level) preceeds clinical loss of response• No severe infusion reactions • Acute severe infusion reactions are due to high ADA levels
  14. 14. Summary High level of innovations @ KU Leuven Unique situation with UZLeuven Translational funding and support available to bridge the development gap (i.e. IOF) Be innovative, make use of academic key enabling technology centers & believe your own data www.pharmabs.org

×